Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct;8(2):e001114.
doi: 10.1136/jitc-2020-001114.

Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2

Michael Wang  1 , Preetesh Jain  2 , T Linda Chi  3 , Sheree E Chen  2 , Amy Heimberger  4 , Shiao-Pei Weathers  5 , Lianqing Zheng  6 , Arati V Rao  7 , John M Rossi  8
Affiliations
Case Reports

Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2

Michael Wang et al. J Immunother Cancer. 2020 Oct.

Abstract

Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed/refractory mantle cell lymphoma. We describe a 65-year-old patient in ZUMA-2 who developed cerebral edema following CAR T-cell therapy and had complete recovery after multimodality clinical intervention including rabbit antithymocyte globulin (ATG). Biomarker results show early and robust CAR T-cell expansion and related induction of inflammatory cytokines, followed by rapid declines in CAR T-cell and proinflammatory cytokine levels after ATG administration. This clinical profile highlights a potential relevance of ATG in treating severe CAR T-cell-related neurotoxicity.

Trial registration: ClinicalTrials.gov NCT02601313.

Keywords: case reports; chimeric antigen.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MW: honoraria from Pharmacyclics, Janssen, AstraZeneca, OMI, and Targeted Oncology; consultancy or advisory role for Pharmacyclics, Celgene, Janssen, AstraZeneca, MoreHealth, Pulse Biosciences, Nobel Insights, and Guidpoint Global; research funding from Pharmacyclics, Janssen, Novartis, Juno, Celgene, Loxo Oncology, VelosBio, and Verastem; expert testimony for AstraZeneca; and travel support from Janssen, Pharmacyclics, Celgene, and OMI. TLC: honoraria from Kite, a Gilead Company; consultancy or advisory role for Kite, a Gilead Company. AH: employment at M.D. Anderson; stock or other ownership in Caris; consultancy or advisory role for Caris and WCG Oncology; research funding from Merck; patents, royalties, or other intellectual property from Celldex. LZ and AVR: employment with Gilead Sciences. JMR: employment with Kite, A Gilead Company; stock or other ownership in Gilead Sciences.

Figures

Figure 1
Figure 1
Timeline of clinical events and interventions in the patient treated with ATG. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATG, antithymocyte globulin; BID, two times per day; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; FLAIR, fluid-attenuated inversion recovery; N/A, not available.
Figure 2
Figure 2
Levels of transaminases, CAR T cells, and cytokines over time. (A) ALT levels in the patient with ATG across the first 17 days post-KTE-X19. (B) Levels of CAR T cells in blood by PCR over the first 6 months following KTE-X19 infusion. In the broader ZUMA-2 population, 66, 65, 59, 65, and 43 patients had data available at days 0 (pre-KTE-X19), 7, 14, 28, and 180, respectively. Levels of IFN-γ (C) and MCP-1 (D) by ELISA over the first 28 days post-KTE-X19. In the broader ZUMA-2 population, 65, 65, 62, 61, 60, and 64 patients had data available at days −4 (pre-conditioning), 0 (pre-KTE-X19), 7, 14, 28, and 180, respectively. ALT, alanine aminotransferase; ATG, anti-thymocyte globulin; CAR, chimeric antigen receptor; ELISA, enzyme-linked immunosorbent assay; IFN-γ, interferon gamma; IL-2, interleukin 2; LOD, limit of detection; MCP-1, monocyte chemoattractant protein 1.
See this image and copyright information in PMC

References

    1. Locke FL, Ghobadi A, Jacobson CA, et al. . Long-Term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20:31–42. 10.1016/S1470-2045(18)30864-7 - DOI - PMC - PubMed
    1. Kochenderfer JN, Somerville RPT, Lu T, et al. . Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther 2017;25:2245–53. 10.1016/j.ymthe.2017.07.004 - DOI - PMC - PubMed
    1. Schuster SJ, Bishop MR, Tam CS, et al. . Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380:45–56. 10.1056/NEJMoa1804980 - DOI - PubMed
    1. Wang M, Munoz J, Goy A, et al. . KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382:1331–42. 10.1056/NEJMoa1914347 - DOI - PMC - PubMed
    1. Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol 2019;94:S42–9. 10.1002/ajh.25445 - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources